BRPI9914741A - n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas. - Google Patents

n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.

Info

Publication number
BRPI9914741A
BRPI9914741A BRPI9914741A BRPI9914741A BRPI9914741A BR PI9914741 A BRPI9914741 A BR PI9914741A BR PI9914741 A BRPI9914741 A BR PI9914741A BR PI9914741 A BRPI9914741 A BR PI9914741A BR PI9914741 A BRPI9914741 A BR PI9914741A
Authority
BR
Brazil
Prior art keywords
sulfonamides
aryl
proprionyl
pharmaceutical compositions
compositions containing
Prior art date
Application number
BRPI9914741A
Other languages
English (en)
Inventor
Riccardo Bertini
Cinzia Bizzarri
Vilma Sabbatini
Stefano Porzio
Gianfranco Caselli
Marcello Allegretti
Maria Candida Cesta
Carmelo A Gandolfi
Marco Mantovanini
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of BRPI9914741A publication Critical patent/BRPI9914741A/pt
Publication of BRPI9914741B1 publication Critical patent/BRPI9914741B1/pt
Publication of BRPI9914741B8 publication Critical patent/BRPI9914741B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

patente de invenção: <b>"n-(2-aril-propionil)-sulfonamidas e preparações farmacêuticas contendo as mesmas"<d>. os compostos de fórmula 1, em que r e r~ 2~ são como definidos na descrição, são úteis na prevenção e no tratamento de lesão tecidual devida ao recrutamento exacerbado de neutrófilos polimorfonucleares (leucócitos pmn) nos sítios de inflamação.
BRPI9914741 1998-10-23 1999-10-14 n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas. BRPI9914741B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998MI002280A IT1303249B1 (it) 1998-10-23 1998-10-23 Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
PCT/EP1999/007740 WO2000024710A1 (en) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Publications (3)

Publication Number Publication Date
BRPI9914741A true BRPI9914741A (pt) 2001-07-03
BRPI9914741B1 BRPI9914741B1 (pt) 2012-11-27
BRPI9914741B8 BRPI9914741B8 (pt) 2021-07-06

Family

ID=11380926

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9914741 BRPI9914741B8 (pt) 1998-10-23 1999-10-14 n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.

Country Status (26)

Country Link
US (2) US6887903B1 (pt)
EP (1) EP1123276B1 (pt)
JP (1) JP4194761B2 (pt)
KR (1) KR100484370B1 (pt)
CN (2) CN100368394C (pt)
AT (1) ATE230723T1 (pt)
AU (1) AU769850B2 (pt)
BR (1) BRPI9914741B8 (pt)
CA (1) CA2347752C (pt)
CZ (1) CZ296434B6 (pt)
DE (1) DE69904852T2 (pt)
DK (1) DK1123276T3 (pt)
EE (1) EE04912B1 (pt)
ES (1) ES2190264T3 (pt)
HK (1) HK1041255B (pt)
HU (1) HU225107B1 (pt)
IL (1) IL142496A0 (pt)
IT (1) IT1303249B1 (pt)
NO (1) NO327537B1 (pt)
NZ (2) NZ511077A (pt)
PL (1) PL212210B1 (pt)
PT (1) PT1123276E (pt)
RU (1) RU2255084C2 (pt)
SK (1) SK286372B6 (pt)
TR (1) TR200101124T2 (pt)
WO (1) WO2000024710A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318466B1 (it) * 2000-04-14 2003-08-25 Dompe Spa Ammidi di acidi r-2-(amminoaril)-propionici, utili nella prevenzionedell'attivazione leucocitaria.
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
DK1581474T3 (da) * 2002-12-10 2008-12-08 Dompe Spa Chirale arylketoner i behandlingen af neutrofilt afhængige inflammatoriske sygdomme
EP1457485A1 (en) * 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonic acids, their derivatives and pharmaceutical compositions containing them
US7271188B2 (en) 2003-06-12 2007-09-18 Chugai Seikayu Kabushiki Kaisha Imidazolidine derivatives
ATE444286T1 (de) 2004-03-23 2009-10-15 Dompe Pha R Ma Spa Res & Mfg 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung
PT1579859E (pt) * 2004-03-25 2007-03-30 Dompe Pha R Ma Spa Res & Mfg Utilização de n-(2-aril-propionil)-sulfonamidas pata o tratamento de lesões da medula espinal
NZ555502A (en) 2004-12-15 2010-12-24 Dompe Pha R Ma Spa Res & Mfg 2-arylpropionic acid derivatives and pharmaceutical compositions containing them
ATE433438T1 (de) * 2005-01-25 2009-06-15 Dompe Pha R Ma Spa Res & Mfg Metaboliten aus 2-arylpropionsäure-derivaten und pharmazeutische zusammensetzungen damit
RU2458051C2 (ru) * 2005-11-24 2012-08-10 ДОМПЕ ФА.Р.МА С.п.А. (r)-арилалкиламинопроизводные и содержащие их фармацевтические композиции
WO2010009212A1 (en) * 2008-07-17 2010-01-21 Schering Corporation Niacin derivatives useful to treat metabolic syndromes
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
EP2308485A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
CN103159652B (zh) * 2011-12-19 2016-06-08 天津市国际生物医药联合研究院 亚磺酰胺类化合物的制备及其应用
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
CN103172547B (zh) * 2011-12-20 2016-10-12 天津市国际生物医药联合研究院 磺酰胺衍生物的制备及其应用
CN103159674A (zh) * 2013-04-03 2013-06-19 苏州安诺生物医药技术有限公司 2-苯烷酰胺类化合物及其制备方法、药物组合物和用途
WO2017121838A1 (en) * 2016-01-15 2017-07-20 Dompe' Farmaceutici S.P.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
US11291641B2 (en) 2016-10-03 2022-04-05 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3409277A1 (en) 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
EP3476390A1 (en) * 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
EP3868369A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
EP3868368A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
EP3884932A1 (en) 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP4008325A1 (en) 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP4125848A1 (en) 2020-03-26 2023-02-08 Dompe' Farmaceutici SpA Cxcl8 inhibitors for use in the treatment of covid-19
IL302553A (en) * 2020-11-05 2023-07-01 Icahn School Med Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4052702A1 (en) 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
EP4397305A1 (en) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
EP4563594A1 (en) 2023-11-28 2025-06-04 Dompe' Farmaceutici SpA Cxcl8 inhibitors for use in the treatment of tumors with low stromal cav1 levels
EP4678171A1 (en) 2024-07-10 2026-01-14 Dompé farmaceutici SpA Systemically-administered cxcl8 inhibitors for use in the prevention or treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
EP4686469A1 (en) 2024-07-31 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities
EP4686472A1 (en) 2024-08-02 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of ocular graft-versus-host disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082707A (en) * 1973-01-08 1978-04-04 Societa Italo-Britannica L. Manetti-H. Roberts & Co. 2-(4-isobutylphenyl)-propiohydroxamic acid and a procedure for its preparation
JPS53111030A (en) * 1977-02-08 1978-09-28 Hisamitsu Pharmaceut Co Inc Novel phenylacetic acid derivatives
US4786316A (en) * 1984-07-13 1988-11-22 E. I. Du Pont De Nemours And Company Herbicidal ortho-sulfamoyl sulfonamides
US5006542A (en) * 1988-10-31 1991-04-09 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, derivatives thereof, compositions containing same and method of use
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
CN1192140A (zh) * 1995-08-04 1998-09-02 沃尼尔·朗伯公司 氨基磺酸衍生物、酰基磺酰氨或磺酰基氨基甲酸酯在制备降低脂蛋白水平的药物中的用途
DE69634822T2 (de) * 1995-08-22 2006-04-27 Japan Tobacco Inc. Amid-verbindungen und ihre anwendung
EP1019035A4 (en) * 1996-08-21 2001-10-17 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
PT1270565E (pt) * 1997-01-29 2004-09-30 Pfizer Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia

Also Published As

Publication number Publication date
DK1123276T3 (da) 2003-04-28
BRPI9914741B1 (pt) 2012-11-27
HK1041255A1 (zh) 2002-07-05
ITMI982280A0 (it) 1998-10-23
CZ20011441A3 (cs) 2001-10-17
RU2255084C2 (ru) 2005-06-27
JP4194761B2 (ja) 2008-12-10
EP1123276B1 (en) 2003-01-08
JP2002528434A (ja) 2002-09-03
US6887903B1 (en) 2005-05-03
EE04912B1 (et) 2007-10-15
KR100484370B1 (ko) 2005-04-22
SK5382001A3 (en) 2001-12-03
IL142496A0 (en) 2002-03-10
BRPI9914741B8 (pt) 2021-07-06
KR20010086435A (ko) 2001-09-12
US20030216392A1 (en) 2003-11-20
HUP0103793A2 (hu) 2002-03-28
CN100368394C (zh) 2008-02-13
EP1123276A1 (en) 2001-08-16
US6881755B2 (en) 2005-04-19
TR200101124T2 (tr) 2001-10-22
NO20012000L (no) 2001-06-20
PL347947A1 (en) 2002-04-22
PL212210B1 (pl) 2012-08-31
CA2347752C (en) 2009-12-22
HK1041255B (zh) 2008-07-18
ITMI982280A1 (it) 2000-04-23
ATE230723T1 (de) 2003-01-15
NZ511077A (en) 2003-08-29
HU225107B1 (en) 2006-06-28
SK286372B6 (sk) 2008-08-05
AU769850B2 (en) 2004-02-05
NO327537B1 (no) 2009-08-03
WO2000024710A1 (en) 2000-05-04
HUP0103793A3 (en) 2003-09-29
CN1615833A (zh) 2005-05-18
PT1123276E (pt) 2003-04-30
CN1324344A (zh) 2001-11-28
CA2347752A1 (en) 2000-05-04
AU1037500A (en) 2000-05-15
DE69904852D1 (de) 2003-02-13
NO20012000D0 (no) 2001-04-23
IT1303249B1 (it) 2000-11-06
NZ525084A (en) 2004-08-27
DE69904852T2 (de) 2003-11-13
CZ296434B6 (cs) 2006-03-15
ES2190264T3 (es) 2003-07-16
EE200100233A (et) 2002-08-15

Similar Documents

Publication Publication Date Title
BRPI9914741A (pt) n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.
BR0014384A (pt) Compostos para o tratamento da isquémia
BR9811818A (pt) Uso de um composto, composto, e, composição farmacêutica
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
BR9714381A (pt) Derivados de 6-fenilpiridil-2-amina
BR9707958A (pt) Composto, composição farmacêutica, e, processo para tratar hiperalgesia em um paciente.
YU57600A (sh) Derivarti biciklične hidroksaminske kiseline
BR9810712A (pt) Processo para a prevenção ou tratamento de prurido em um paciente
FI970825A7 (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyö tyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
EE200100007A (et) Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis
BR9808366A (pt) Derivados de ácido hidroxâmico substituìdo com aril ou heteroaril sulfonamidas; processo para sua preparação e seu uso como produtos farmacêuticos
ATE243196T1 (de) Piperidine und pyrrolidine
GR3036184T3 (en) Heterocyclic diaryl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
DK0832057T3 (da) Diaromatiske propynyl- eller dienylforbindelser
BR9812160A (pt) Derivados de benzoxazina e benzotiazina e seu emprego em medicamentos
FR2794976B1 (fr) Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
BR9916733A (pt) Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm
BR0000901A (pt) Derivados 4-fenil-4-heteroarilpiperidina
AP9801235A0 (en) Erythromycin derivatives.
BRPI0012329B8 (pt) derivados de benzofurano, processo para sua preparação e uso dos mesmos.
BR9813897A (pt) Derivados de bifenila como farmacêuticos
BR0011049A (pt) Fenilciclohexanocarboxamidas substituìdas e seu uso como inibidores de absorção de adenosina

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/11/2012, MEDIANTE O RECOLHIMENTO DA TAXA QUINQUENAL DE MANUTENCAO (ARTIGOS 119 E 120 DA LPI) E OBSERVADAS AS DEMAIS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/10/99, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 23A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2692 DE 09-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.